HOME >> BIOLOGY >> NEWS
Potent new compound from blue-green algae may help treat, elucidate nerve disorders

Click here for abstract.

HONOLULU, Dec. 19 - Amid a growing list of biologically useful chemicals from the sea, a newly discovered compound - kalkitoxin - stands out for its potential to help researchers understand nerve function, which could someday lead to new treatments for pain, epilepsy and possibly stroke. The finding was reported here today at the 2000 International Chemical Congress of Pacific Basin Societies.

The weeklong scientific meeting, held once every five years, is hosted by the American Chemical Society, in conjunction with its counterparts in Australia, Canada, Japan and New Zealand.

Lead investigator William Gerwick, Ph.D., a pharmacy professor at Oregon State University in Corvallis, says the neurotoxin - a metabolite in cyanobacteria - is fundamentally new in both structure and potency.

"What we've found is a spectacularly potent neurotoxin, meaning kalkitoxin can kill neurons," explained Gerwick. "And when a compound is very toxic, it's working by a very specific mechanism." He and his collaborators hope to use that mechanism "to dissect neurochemical pathways and to understand how drugs affect them," he said.

Their discovery began "in an absolutely beautiful bay" of the Caribbean island of Curacao, near Venezuela, Gerwick said. "In 1994, we found a collection of cyanobacteria growing like hairs off the sea floor. We brought several liters of it back to Oregon for testing." Marine cyanobacteria, also called blue-green algae, are most familiar to many people as "pond scum."

Back in the laboratory, Gerwick's team ground up samples of the simple plant and tested extracts on brine shrimp and fish. One extract proved toxic even in concentrations of parts per billion. The researchers named the as-yet-mysterious compound after the island's Kalki Bay
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
808-944-6381
American Chemical Society
18-Dec-2000


Page: 1 2

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potent toxin reveals new antibiotic resistance mechanism
3. Potential blood test for colon cancer risk
4. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
5. Potential cause of arthritis discovered
6. Potential of regenerative medicine explored
7. Potential therapy reported for children, adults with end-stage liver disease
8. Potential allergy vaccine boosts hope for sufferers
9. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
10. Potential new anthrax therapy discovered
11. Potential gene therapy carriers created that mimic viruses, without the risk

Post Your Comments:
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
(Date:3/5/2015)... NORWALK, Conn. , March 5, 2015 /PRNewswire/ ... Network , a leading online community to ... understanding of the newest information available regarding the ... coverage of kidney cancer. March is ... there are very few effective adjuvant treatment options ...
(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
Cached News: